Patient Expectations and Perceptions of Goal-setting Strategies for Disease Management in Rheumatoid Arthritis.

CONCLUSION: Many patients with RA feel unable to communicate their disease burden and treatment goals, which are critically important to them, to their healthcare provider (HCP). Insights gained from these 2 surveys should help to guide patients and HCP to better focus upon mutually defined goals for continued improvement of management and achievement of optimal care in RA. PMID: 26233504 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Tags: J Rheumatol Source Type: research

Related Links:

CONCLUSIONS: Disease burden in patients with PsA or axSpA was comparable to or greater than that in patients with RA on the basis of common patient-reported outcome measures but appeared lower when assessed using RA disease activity measures, suggesting that disease-specific approaches to care are needed to optimize disease management. FUNDING: This study was sponsored by Corrona, LLC, and financial support was provided by Novartis. The Rapid Service Fee was funded by Novartis. Plain language summary available for this article. PMID: 31529278 [PubMed - as supplied by publisher]
Source: Pain Physician - Category: Anesthesiology Authors: Tags: Rheumatol Ther Source Type: research
ConclusionsDisease burden in patients with PsA or axSpA was comparable to or greater than that in patients with RA on the basis of common patient-reported outcome measures but appeared lower when assessed using RA disease activity measures, suggesting that disease-specific approaches to care are needed to optimize disease management.FundingThis study was sponsored by Corrona, LLC, and financial support was provided by Novartis. The Rapid Service Fee was funded by Novartis.Plain Language SummaryPlain language summary available for this article.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
Conclusion: Rheumatologists highly valued patient-reported RA symptoms and physical function to inform their treatment decisions, even above objective data such as physical findings and test results. These results can guide the selection of validated PRO measures to assess these domains to inform the clinical care of patients with rheumatoid arthritis. PMID: 31517249 [PubMed]
Source: Pain Physician - Category: Anesthesiology Authors: Tags: BMC Rheumatol Source Type: research
AbstractPolymyalgia rheumatica is an inflammatory rheumatic disease of the elderly characterised by pain and stiffness in the neck and pelvic girdle, and is the second most common inflammatory rheumatic condition in this age group, after rheumatoid arthritis. Polymyalgia rheumatica can occur independently or in association with giant cell arteritis, which is the most common form of primary vasculitis. The diagnosis of polymyalgia rheumatica is usually based on clinical presentation and increase of inflammatory markers. There are no pathognomonic findings that can confirm the diagnosis. However, different imaging techniques...
Source: Drugs and Aging - Category: Geriatrics Source Type: research
AbstractRheumatoid arthritis (RA) is a systemic, autoimmune disease that affects joints and extra-articular structures. In the last decade, the management of this chronic disease has dramatically changed with the introduction of several targeted mechanisms of action, such as tumor necrosis factor- α inhibition, T-cell costimulation inhibition, B-cell depletion, interleukin-6 blockade, and Janus kinase inhibition. Beyond its well-known hematopoietic role on the proliferation and differentiation of myeloid cells, granulocyte-monocyte colony-stimulating factor (GM-CSF) is a proinflammatory medi ator acting as a cytokine...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 30 August 2019Source: The Egyptian RheumatologistAuthor(s): Hanan M. Elshoura, Nayera Z. Saber, Mohamed A. Elwy, Mervat M. AbdelhakimAbstractAim of the workTo assess the effectiveness of perineural injection therapy (PIT) as a new modality in the management of chronic pain and dysfunction of the TMJ in RA patients and to study if it has any role in tissue regeneration.Patients and methodsOut of 19 RA patients with persistent TMJ involvement and pain despite receiving systemic treatment, 13 agreed to have PIT and only 11 completed the study; 21 TMJ (10 bilateral and 1 unilateral) were asse...
Source: The Egyptian Rheumatologist - Category: Rheumatology Source Type: research
This issue of the Rheumatic Disease Clinics of North America has broken ground in the area of process management of our diseases. The remarkable success of the treat-to-target approach in rheumatoid arthritis has led to increased speculation: can it be applied to our other rheumatic diseases, which may be more heterogeneous (in some cases) or where the targets are less obvious or more multidimensional? The assumption that control of inflammation, by its very nature, can lead to the optimum result of damage prevention makes intuitive sense, but at what level is the inflammation judged to be important? Should we use highly s...
Source: Rheumatic Disease Clinics of North America - Category: Rheumatology Authors: Tags: Foreword Source Type: research
Conclusion: The expression of all chemical mediators are directly related to RA and the modulation of pain by a complex intra and extracellular signaling pathway, however, transcription factors are involved in acute pain, while the ionic channels are involved in chronic pain in RA. . PMID: 31419924 [PubMed - as supplied by publisher]
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research
Date: September 23, 2019 Issue #:  1581Summary:  The FDA has approvedQmiiz ODT (TerSera), an orally disintegrating tablet formulation of the prescription NSAID meloxicam.Qmiiz ODT, like conventional oral meloxicam tablets (Mobic, and generics), is indicated for relief of the symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA) in adults and of juvenile RA in children who weigh≥60 kg.Vivlodex, a low-dose capsule formulation of meloxicam, is FDA-approved only for management of OA pain.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Meloxicam Mobic NSAIDs Osteoarthritis Qmiiz ODT Rheumatoid arthritis Vivlodex Source Type: research
ConclusionsResults from this real-world survey suggest that three-fourths of RA patients are not satisfied with treatments, which include bDMARDs. Patients continued to experience bothersome symptoms that impacted their daily activities and life. There remains a need for improved disease management among currently treated RA patients.FundingEli Lilly and Company (Indianapolis, IN, USA).
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
More News: Arthritis | Pain | Pain Management | Rheumatoid Arthritis | Rheumatology | Women